Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ultragenyx Pharmaceutical (RARE) Operating Margin (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Operating Margin for 10 consecutive years, with 54.65% as the latest value for Q4 2025.

  • On a quarterly basis, Operating Margin rose 1963.0% to 54.65% in Q4 2025 year-over-year; TTM through Dec 2025 was 79.49%, a 1622.0% increase, with the full-year FY2025 number at 79.49%, up 1622.0% from a year prior.
  • Operating Margin was 54.65% for Q4 2025 at Ultragenyx Pharmaceutical, up from 106.85% in the prior quarter.
  • In the past five years, Operating Margin ranged from a high of 54.65% in Q4 2025 to a low of 248.14% in Q3 2022.
  • A 5-year average of 120.83% and a median of 108.62% in 2021 define the central range for Operating Margin.
  • Peak YoY movement for Operating Margin: soared 22511bps in 2021, then plummeted -13812bps in 2022.
  • Ultragenyx Pharmaceutical's Operating Margin stood at 122.99% in 2021, then fell by -15bps to 140.91% in 2022, then skyrocketed by 32bps to 95.83% in 2023, then rose by 22bps to 74.28% in 2024, then increased by 26bps to 54.65% in 2025.
  • Per Business Quant, the three most recent readings for RARE's Operating Margin are 54.65% (Q4 2025), 106.85% (Q3 2025), and 64.8% (Q2 2025).